| Keywords: |
protein expression; genetics; follow up; t lymphocyte; t-lymphocytes; multiple myeloma; cell maturation; editorial; cytotoxicity; food and drug administration; t lymphocyte receptor; antigen recognition; retrovirus vector; chimeric antigen receptor; cell therapy; adoptive immunotherapy; immunotherapy, adoptive; hla antigen; t lymphocyte activation; cd28 antigen; nuclear reprogramming; cell surface; molecularly targeted therapy; phase 2 clinical trial (topic); phase 1 clinical trial (topic); cd56 antigen; cd137 ligand; overall response rate; humans; human; b cell maturation antigen; adp ribosyl cyclase/cyclic adp ribose hydrolase 1; b-cell maturation antigen; receptors, chimeric antigen; ciltacabtagene autoleucel; idecabtagene vicleucel
|
